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Abstract
Controlled human malaria infection (CHMI) in healthy human volunteers is an important and
powerful tool in clinical malaria vaccine development. However, power calculations are
essential to obtain meaningful estimates of protective efficacy, while minimizing the risk of
adverse events. To optimize power calculations for CHMI-based malaria vaccine trials, we
developed a novel non-linear statistical model for parasite kinetics as measured by qPCR,
using data from mosquito-based CHMI experiments in 57 individuals. We robustly account
for important sources of variation between and within individuals using a Bayesian frame-
work. Study power is most dependent on the number of individuals in each treatment arm;
inter-individual variation in vaccine efficacy and the number of blood samples taken per day
matter relatively little. Due to high inter-individual variation in the number of first-generation
parasites, hepatic vaccine trials required significantly more study subjects than erythrocytic
vaccine trials. We provide power calculations for hypothetical malaria vaccine trials of vari-
ous designs and conclude that so far, power calculations have been overly optimistic. We
further illustrate how upcoming techniques like needle-injected CHMI may reduce required
sample sizes.
Author Summary
Controlled human malaria infection (CHMI) in healthy human volunteers is an impor-
tant and powerful tool in clinical malaria vaccine development. However, to obtain mean-
ingful estimates of protective efficacy, it is important to include an appropriate minimum
number of participants, while minimizing the risks and burden for volunteers. Existing
power calculations have limited value due to important influential assumptions. To opti-
mize power calculations for malaria vaccine trials, we developed a non-linear, Bayesian
statistical model for parasite kinetics as measured by quantitative real-time polymerase
chain reaction, using existing data from mosquito-based CHMI experiments. Using our
model, we provide improved, robust power calculations for various hypothetical malaria
vaccine trials, taking account of important sources of variation between and within indi-
viduals. We conclude that so far, power calculations for malaria vaccine trials have been
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overly optimistic. We further illustrate how upcoming techniques like needle-injected
CHMI may reduce required sample sizes.
Introduction
In 2015, malaria caused an estimated 438,000 deaths (236,000–635,000) [1], most of which
were associated with Plasmodium falciparum (Pf) infections. Hypothetically, a malaria vaccine
targeting the sporozoite parasite stage (pre-hepatic vaccine), hepatic parasite stage (hepatic
vaccine), and/or blood stage parasites (erythrocytic vaccine) could prevent many such deaths.
In the past ten years, over 40 malaria vaccines have reached the clinical trial stage. So far, only
the RTS,S vaccine has shown promising results (30%–65% protection against clinical malaria)
[2–6], with a recent large, multi-center phase three trial showing 45.7% protection against clin-
ical malaria in infants and children aged 5–17 months over a period of 18 months after three
vaccine doses [7]. In response, the World Health Organization has recommended RTS,S for
pilot implementation studies in Africa [8]. However, before any malaria vaccine can be tested
in the field, its efficacy and safety need to be evaluated in controlled settings, which is most
often done by means of controlled human malaria infection (CHMI) [9,10].
CHMI is currently considered to be a powerful tool in clinical vaccine development, as it
allows researcher to control the otherwise highly variable infection rates. It is traditionally con-
ducted by exposing a limited number of volunteers to laboratory-reared Anopheles spp. mos-
quitoes carrying Pf sporozoites [10,11], and more recently, also through needle injection of a
defined number of aseptic cryopreserved sporozoites [12,13]. Parasitaemia can be monitored
by means of blood smear microscopy but increasingly by sensitive quantitative real-time poly-
merase chain reaction (qPCR) [14–17]. The traditional study endpoint is detection of blood
stage parasites by microscopy, at which point a study subject is treated with a curative regimen
of an anti-malarial drug [10]. Under these conditions and with some additional precautionary
measures, CHMI studies are considered to be safe, though the risk of severe adverse effects
and the burden of venipuncture up to three times per day have to be weighed against the bene-
fits of the information to be gained [18–20]. Power calculations for CHMI-based vaccine trials
are therefore critical to ensure an appropriate number of included participants to obtain mean-
ingful estimates of protective efficacy.
Here we provide an optimized method for power calculations for CHMI-based hepatic and
erythrocytic vaccine trials in malaria-naive individuals, using qPCR and bloodsmear data from
mosquito-based CHMI experiments in 57 non-vaccinated individuals. We developed a novel
non-linear model for parasite kinetics during the first two weeks of an experimental infection,
based on an earlier statistical model for cyclical patterns in CHMI [21]. We implemented the
model in a Bayesian hierarchical framework to capture important sources of variation both
within and between individuals (i.e. by means of random effects), and extended the model to
explicitly capture the processes leading to measurements below the qPCR detection limit (cen-
soring) and termination of the experiment due to positive blood microscopy. With this model,
we performed power calculations for hypothetical hepatic and erythrocytic malaria vaccine tri-
als under varying assumptions about blood sampling schemes and vaccine impact on parasite
growth.
Results
In Fig 1 we provide an example of the model fit to the data for a subset of individuals, and
illustrates the cyclical pattern in both the data and model predictions. Note how censored
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observations (black triangles) coincide with model predictions near or under the qPCR detec-
tion limit (dashed line). Similar plots for all individuals can be found in S1 Fig. For a minority
of subjects no clear cyclical pattern in parasitaemia levels was visible, resulting in relatively
wide credible intervals for predicted parasitaemia levels. Data from one individual were
excluded (ZONMW1.1270) because they were prohibitively divergent from the rest to effec-
tively fit the model (first observation above detection limit at day ten and no clear cyclical pat-
tern while this individual–like all others–had no vaccine protection). S2 Fig depicts the
association between parasite concentration in the blood and probability of positive blood
microscopy in comparison to the data, illustrating good agreement between the model and the
data.
We estimated that the average number of first generation parasites among the 56 included
study subjects was 635 Pf/ml (95%-BCI 406–945; Table 1). Inter-individual variation in the
number of first generation parasites was estimated at a standard deviation (SD) of 1.40 on
the natural logarithmic scale, which is equivalent to a relative standard deviation (RSD) of
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
expð1:402Þ   1
p
¼ 247%. Assuming that infected hepatocytes release on average 6.0 merozo-
ites per mL blood (based on 30,000 merozoites per hepatocyte and an average of 5 litres of
blood per person, as assumed before [21]), we can deduce from the average concentration of
first generation parasite that on average about 107 hepatocytes were infected and that each
experimentally infected mosquito transmitted on average about 21 sporozoites (that success-
fully infected hepatocytes). The average time of appearance of first-generation parasites was at
day 6.87 (95%-BCI 6.76–6.99), with little variation between individuals (SD 0.036, RSD 3.6%).
The average multiplication rate of P. falciparum parasites within individuals was estimated at
11.8 per parasite cycle (95%-BCI 9.0–15.3), with inter-individual variation estimated at a SD of
0.47 on the natural logarithmic scale (RSD 50%).
Fig 1. Example model predictions for blood parasite levels in a subset of individuals. Black bullets represent
data points; black triangles are observations below the detection limit (dashed line). The solid black line represents
the posterior mean. The shaded band around it represents the 2.5th and 97.5th percentiles of the predicted parasite
concentrations, based on 8000 draws from the posterior distribution. Panel headers refer to unique identifiers for
CHMI volunteers, which can also be found in the data (S1 File).
doi:10.1371/journal.pcbi.1005255.g001
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In Fig 2, we illustrate the correlation between time of appearance of first generation blood
parasites, peak concentration in blood of first generation parasites, the parasite multiplication
rate, and the relative odds of an individual having positive blood microscopy. As there was no
clear correlation pattern between these four individual-level parameters, we did not further
explicitly model their joint distribution (i.e. we assume they are independently distributed
when simulating data for power calculations).
Next, we used the model to simulate ten thousand repeated data sets for each of various
hypothetical vaccine trial designs. In each simulated vaccine trial, we define vaccine efficacy as
the relative reduction in total number of released merozoites induced by a hepatic vaccine, or
the relative reduction in parasite growth rate induced by an erythrocytic vaccine. To explicitly
account for previously excluding one out of 57 original study subjects, we allowed each indi-
vidual in the simulated vaccine trials to be dropped with a 1/57 probability (which turned
out to be of little consequence for power estimates). Fig 3 illustrates how trial power increases
with the number of individuals per trial arm, allowing one to deduce the required number of
individuals for a desired power level. Study power is most dependent on the number of indi-
viduals in each treatment arm; in contrast, inter-individual variation in vaccine efficacy and
the number of blood samples taken per day matter relatively little for study power. Due to
high inter-individual variation in the number first-generation parasites, hepatic vaccine trials
required significantly more study subjects than erythrocytic vaccine trials. For instance, over
Table 1. Parameter estimates for parasite kinetics in mosquito-based, controlled human malaria infection.
Parameter Interpretation Posterior
mean
95%-BCI
Number of first generation parasites per mL blood
β1 Population geometric mean 635 406–945
sb1 Inter-individual variation (on natural logarithmic scale) 1.40 1.12–1.74
Parasite multiplication rate per cycle
β2 Population geometric mean 11.8 9.0–15.3
sb2 Inter-individual variation (on natural logarithmic scale) 0.47 0.27–0.70
Time of appearance of first generation parasites (days)
μ1 Population geometric mean 6.87 6.76–6.99
sm1 Inter-individual variation (on natural logarithmic scale) 0.036 0.025–
0.046
σ1 Variation in time of appearance of individual first generation parasites (inversely related to rate at which parasite
concentrations rise and fall within individuals)
0.24 0.20–0.28
Parasite generation time
μ2 Blood stage duration (days) 1.19 1.04–1.34
μ3 Sequestration duration (days) 0.66 0.53–0.79
μ23 Total generation time (μ2 + μ3) 1.84 1.79–1.91
Measurement error
σy Measurement error in natural logarithm of parasite blood concentration 0.98 0.90–1.07
Probability of positive blood microscopy
αTS Population-average log-odds of positive blood microscopy in case of 1 parasite per mL blood -11.3 -15.1 –-8.4
σTS Inter-individual variation in log-odds of positive blood microscopy 0.52 0.03–1.3
βTS Log-odds ratio of positive blood microscopy per unit increase in natural logarithm of parasite blood
concentration
1.2 0.9–1.7
Bayesian credible intervals (BCI) are defined as the 2.5th and 97.5th percentiles of the posterior sample for each parameter. All estimates of variation
(including measurement error) are expressed in terms of standard deviations on the natural logarithmic scale, unless specified otherwise. For information on
the assumed prior distributions and a detailed description of the statistical model, see S1 Text and Table S1 within it.
doi:10.1371/journal.pcbi.1005255.t001
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30 individuals per trial arm are needed to achieve 80% study power when hepatic vaccine effi-
cacy is 70% or lower. S2 File provides a graphical user interface to look up power of all simu-
lated vaccine trial settings. The effective probability of a Type 1 error when using T-tests
Fig 2. Matrix scatter plot of random effects for sources of inter-individual variation. Random effects (x-axes and y-axes) pertain to the average time
of appearance of first generation blood parasites, the number of first cycle parasites, the multiplication rate of blood parasites, and the log-odds ratio of an
individual having parasites detected during blood microscopy, adjusted for predicted parasite levels. Within each panel, each bullet represents the point
estimate for one CHMI volunteer (N = 56), based on the mean of 8000 draws from the posterior.
doi:10.1371/journal.pcbi.1005255.g002
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Fig 3. Simulated vaccine trial power to detect a statistically significant difference between an intervention and control group (T-test
assuming unequal variances, setting α = 0.05). Simulations were performed for each combination of vaccine type (erythrocytic or hepatic), efficacy
(50%, 60%, 70%, 80%, or 90% reduction in first-generation parasite loads or parasite multiplication rate), variation in efficacy between individuals
(standard deviation or SD), and the frequency of blood samples taken: one per two days (8am or 4pm), or one (8am), two (8am, 4pm), or three (8am,
4pm, 10pm) per day. Power calculations for a wider range of vaccine efficacy (30%–95%) can be visualized with the graphical user interface in S2 File.
doi:10.1371/journal.pcbi.1005255.g003
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(assuming unequal variances and setting α = 0.05) was approximately 5% and even somewhat
lower for small sample sizes (S3 Fig), which confirmed the validity of T-tests for identifying a
difference between trial arms.
S4 Fig also depicts the association between trial power and number of individuals per treat-
ment arm (like Fig 3), but under the assumption that inter-individual variation in peak first-
generation parasite density in terms of SD is halved (e.g. by using needle-injected instead of
mosquito-based CHMI). This figure illustrates how such a reduction in inter-individual varia-
tion may reduce the number of individuals required for hepatic vaccine trials. For instance,
only 11 to 15 individuals per trial arm (depending on number samples per day) would be
needed to achieve 80% study power when hepatic vaccine efficacy is 70%, instead of around 30
or more when using mosquito-based CHMI (Fig 3).
For comparison, we further repeated the power analysis using the log-linear sine model
[22], which we also improved to explicitly capture censored observations and inter-individual
variation in slope, intercept, and timing of the log-linear sine curve. Table S2 in S1 Text sum-
marizes the assumed prior distributions and posterior parameter estimates for the sine model;
S5 Fig depicts the model fit to the data. The log-linear sine model resulted in a higher estimate
of the parasite growth rate than our non-linear model: 4.80 per day, or 17.9 per parasite cycle
(vs. 11.8 per cycle), assuming a parasite cycle duration of 1.84 days (as estimated by the non-
linear model). Further, the sine model resulted in a higher estimate of qPCR measurement
error (1.22 vs. 0.98 on the natural logarithmic scale, or RSD of 155% vs. 129%), which is an
indication of the sine model providing an inferior fit to the data compared to the non-linear
model, as it attributed some of the temporal variation in the data to (random) measurement
error. As a result, the sine model produced more optimistic estimates of study power than our
non-linear model, especially for hepatic vaccines (S6 Fig).
Discussion
We present robust power analyses for malaria vaccine trials based on controlled human
malaria infection (CHMI) experiments, using a Bayesian non-linear model for blood parasite
kinetics. Our model adequately accounts for the cyclical nature of P. falciparum concentrations
in the host blood, based on robust estimates of biological parameters underlying CHMI. Our
study supersedes earlier models and power calculations: we prevent overly optimistic estimates
of trial power by directly modeling the biological processes behind the cyclical patterns in
CHMI to best capture temporal patterns in the data, and by jointly and robustly estimating all
model parameters in a Bayesian hierarchical model framework. Furthermore, we avoid exces-
sive weighing of outliers in data simulation, appropriately model the impact of detection limits,
and account for five important sources of variation between individuals: time of first parasite
appearance, first cycle amplitude, parasite multiplication rates, probability of positive blood
microscopy (and consequent termination of the experiment), and vaccine efficacy. This makes
our model a more suitable tool for power calculations of CHMI-based vaccine trials than pre-
vious approaches to date.
Our study confirms that for vaccine trial power, inter-individual variation in vaccine effi-
cacy and the number of blood samples taken per day matter relatively little, and that erythro-
cytic vaccine trials require significantly fewer study subjects than hepatic vaccine trials [23].
Importantly, our analyses suggest that loss of only a few study subjects (e.g. due to experimen-
tal failure) may lead to drastic loss of trial power, unless the trial power is already close to
100%, which is important to consider during trial design. For instance, if the anticipated effi-
cacy of a hepatic vaccine is 80% (reduction in number of first-generation parasites), 15 people
per treatment arm will provide just over 80% power to detect this level of efficacy, but drop out
The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection
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of even one study subject per treatment arm may diminish the trial power below 80%. Further,
our results suggest that a 50% reduction in the inter-individual variation of the number of
first-generation parasites (e.g. by using needle-injected instead of mosquito-based CHMI) may
result in a substantial reduction in the number of individuals required per trial arm, especially
so for hepatic vaccine trials (reductions up to 50%). These estimates will be further refined
based on forthcoming data from needle-injected CHMI experiments.
The average multiplication rate of P. falciparum parasites estimated by our non-linear
model is very similar to earlier estimates [22,24,25] or somewhat higher [21,23,26]. However,
our results do not confirm an earlier report by Sheehy et al. of negative correlation between
the parasite multiplication rate and the peak concentration of first generation parasites in mos-
quito-based CHMI [13], and suggest that this previous finding should be revisited. Possibly,
Sheehy et al. overestimated the multiplication rate in study subjects with low initial parasite
loads (two parasites per mL) as typically, parasite loads below the detection limit for such indi-
viduals are set to some arbitrary low value (e.g. half the value of the detection limit[26]) while
ignoring measurement error (i.e. true levels may be above the detection limit). If Sheehy et al.
had left out observations with low initial parasite loads (<10 Pf/mL) from their analysis, very
little correlation would have remained.
The parameter estimates from our study are intended for power calculations for phase 1/2
hepatic and erythrocytic vaccine trials using CHMI of malaria-naive individuals with NF54 or
similar strains (i.e. first-time infections only), and using qPCR to monitor parasitaemia levels.
To avoid variation due to differences between labs and strains, future vaccine trials using
CHMI should either be performed in a single lab using a single strain (as was the case for the
data used in this study), or in case of multi-center trials, each lab should cover each trial arm to
allow within-lab comparisons. Of course, the validity of power estimates based on our model
relies on understanding one’s potential vaccine efficacy in terms of its impact on the number
of first generation blood parasites and the parasite replication rate at the time of challenge (in
contrast to impact on clinical outcomes such as time until positive blood microscopy or dura-
tion of sterile protection). The potential vaccine efficacy in a power calculation is ideally based
on a target product profile (TPP) defined as part of a vaccine development process. We there-
fore recommend that TPPs are defined not just in terms of clinical outcomes but also in terms
of impact of a vaccine on parasite growth. The link between impact on parasite growth and
clinical outcomes in healthy volunteers and inhabitants of endemic areas is a topic of ongoing
research. Based on our study in health volunteers, however, we can say that to achieve sterile
protection in healthy volunteers, an erythrocytic vaccine would have to reduce the parasite
multiplication rate by at least 92% (1 − 1/β2, where β2 is the parasite multiplication rate per
cycle).
Further, our estimates for biological parameters can be used as prior information (in a
Bayesian framework) in studies that aim to estimate biological and/or vaccine efficacy parame-
ters. If there is reason to believe that the study population is somehow different from the popu-
lation covered by the current study (e.g. a different parasite replication rate is expected), it is
important that a sensitivity analysis be performed by incrementally diluting the relevant prior
information (i.e. increasing prior variance on the population mean and variance of e.g. replica-
tion rates) so that the prior information becomes weaker and the model is relatively more
informed by the data at hand.
Here, we predict that mosquito-based CHMI vaccine trials may require several tens of vol-
unteers per trial arm, especially if the expected vaccine efficacy is under 70% (in terms of impact
on patterns in parasite growth) and/or if a hepatic vaccine is being tested. In our experience and
as reported in literature [27], CHMI experiments are typically executed with 5–8 volunteers at a
time, or in several batches of that size. Working with larger groups is impractical and expensive
The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1005255 January 12, 2017 8 / 15
because many volunteers will turn positive for malaria infection on the same day, requiring
more attending physicians and lab personnel. However, future vaccine candidates should pref-
erably have an impact on parasite growth that is much higher than 70%, which for erythrocytic
vaccines can be demonstrated with 80% power using only 5 to 15 volunteers per trial arm.
Achieving similar study power for hepatic vaccine trials with the same number of volunteers
might be made possible by the use of needle-based CHMI.
It has been argued that the non-linear model that we build on here [21] is unnecessarily
complex as simpler models may yield very similar estimates of relevant biological parameters,
and requires the estimation of vaccine-irrelevant parameters and the assumption that some of
those parameters are fixed [26]. We argue that log-linear models (a straight line through the
log-transformed parasite concentrations [24]) and sine models (log-linear model in which the
slope is multiplied with a sine function [22,28]) are too simple and require assumptions that
clearly contradict the data (linearity of data; data before first parasite generation are ignored;
parasite cycles follow a symmetric, sinusoid pattern), making them less fit for power calcula-
tions. In power analyses, it is imperative to consider uncertainty in all relevant parameters
(like we do here) [29], including the processes leading to censoring of observations below the
detection limit and termination of an experiment in case of positive blood microscopy. In this
study, we demonstrate that the log-linear sine model (even after properly accounting for cen-
soring and variation between individuals) results in higher power estimates than our non-
linear model, which we attribute to the fact that the sine model does not capture temporal pat-
terns in CHMI data as well as our non-linear model, as indicated by the sine model’s higher
estimate for qPCR measurement error. The bootstrapping approach to power calculation used
by Roestenberg et al. [23] is a major improvement over log-linear and sine models, but it is
based on the assumption that the empirical distribution of data observed so far is representa-
tive of the distribution in the population, which may cause it to assign excessive weight to out-
liers in power calculations, especially when based on small datasets. Rather, our model, with its
hierarchical design, shrinks such outliers towards the population mean when estimating popu-
lation-level parameter values, while retaining the ability to simulate such outliers by chance.
Because we more robustly quantify parameter uncertainty, our power estimates are more real-
istic and dictate higher required sample sizes compared to those by Roestenberg et al. [23] Fur-
ther, in the current study, we relaxed the assumption of fixing parameters by jointly estimating
all parameters in a Bayesian framework.
A possible limitation in the application of our model for mosquito-based CHMI data, is the
assumption that first-generation malaria parasites appear in the blood in a single wave (an
assumption shared with the sine model [22,28]). Obviously, this was not the case for subjects
in whom no clear cyclical pattern in parasitaemia levels was visible. In this respect, CHMI data
based on needle-infected PfSPZ may provide less noisy data than mosquito-based CHMI
[12,13], and may even result in fewer asynchronous parasite cycles, although this remains to
be evaluated. In short, like all other statistical models [22–24,28], our model relies on assump-
tions that are not always fulfilled; nevertheless, our model best approximates and quantifies
uncertainty in the biological mechanisms behind CHMI and is therefore the most suitable for
performing power calculations.
As already mentioned, only the RTS,S vaccine has shown promising results so far (30%–
65% protection against clinical malaria) [2–6], with a recent large, multi-center phase three
trial showing 45.7% protection against clinical malaria in infants and children aged 5–17
months over a period of 18 months after three vaccine doses [7]. Unfortunately, RTS,S vaccine
trials have only used blood microscopy to evaluate infection levels in trial participants so far,
which does not allow evaluation of vaccine impact in terms of the effect on parasite growth
patterns (and thus a link with our power analyses). This obstacle may be readily overcome by
The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1005255 January 12, 2017 9 / 15
the use of qPCR to monitor infection levels in Phase 1/2 studies, which may also help to reduce
study sample sizes.
In conclusion, to maximize the probability of identifying effective candidate malaria vac-
cines, and to keep the risk of severe adverse events and the number of invasive procedures to a
minimum, it is important to perform power analyses. With this study, we provide robust
power estimates for malaria vaccine trials using mosquito-based CMHI, superseding previous
models and power analyses. Given the simulation-based nature of our approach, it is straight-
forward to implement more complicated assumptions for future vaccine trials. Last, our model
suggests that using needle-injected instead of mosquito-based CHMI may improve the power
of hepatic vaccine trials.
Materials and Methods
Data and study population
We used data from 57 volunteers participating in 8 different sporozoite challenge trials at Rad-
boud University Medical Center (RUMC, Nijmegen, The Netherlands) from 1999 to 2011
(Table 2) [14,21,30–35]. The data set included subjects from immunological studies (n = 20),
infectivity controls from immunization trials (n = 18), and non-protected subjects from a
malaria vaccine trial (n = 19). Volunteers were challenged by bites of 4–7 (n = 20) or 5 infected
mosquitoes (n = 37) for 10 minutes; the number of bites was unknown as exposure to mos-
quito bites took place in the dark (under a cloth), and not all individuals developed a clearly
visible skin reaction to every bite. Mosquitoes were laboratory-reared and infected with the
NF54 strain of Pf. Presence of sporozoites in mosquitoes was confirmed by salivary gland dis-
section. Trial subjects were followed 2–3 times daily from day 5 after challenge until 3 days
after antimalarial curative treatment. At every visit, blood samples were collected and assessed
for presence of parasites by microscopy (threshold 4 parasites/μL) and quantified by qPCR
(detection limit 20 or 200 parasites/mL) [14]. Ethical approval was obtained for each trial sepa-
rately from the RUMC institutional review board and/or for some trials from the Dutch Cen-
tral Committee on Research Involving Human Subjects (0004–00900, 0011–0262, 2001/203,
2002/170, NCT00442377, NCT00757887, NCT00509158, NCT01002833, NCT01236612).
Statistical model
We modeled parasite kinetics in a novel Bayesian non-linear statistical model, which is based
on a previous, simpler model for cyclical patterns in CHMI [21]. The model predicts parasite
Table 2. Study characteristics.
Study Data
marker
Type* Number of human
volunteers
Number of mosquitoes per
volunteer
Parasite
strain
qPCR Detection
limit
Citation
0004–00900 EHMI-2 CHMI 5 4–7 NF54 20 Pf/ml [14]
0011–0262 EHMI-3 CHMI 5 4–7 NF54 20 Pf/ml [21]
2001/203 EHMI-4 CHMI 5 4–7 NF54 20 Pf/ml [21]
2002/170 EHMI-5 CHMI 5 4–7 NF54 20 Pf/ml [30]
NCT00442377 EHMI-8A CIS 5 5 NF54 20 Pf/ml [31]
NCT00757887 EHMI-8B CIS 5 5 NF54 20 Pf/ml [32]
NCT00509158 LSA3 CIS 18 5 NF54 200 Pf/ml Unpublished
NCT01002833 TIP-1 CHMI 4 5 NF54 20 Pf/ml [33]
NCT01236612 ZonMw CIS 5 5 NF54 20 Pf/ml [34,35]
*CHMI: Controlled Human Malaria Infection; CIS: Controls of an Immunization Study
doi:10.1371/journal.pcbi.1005255.t002
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concentration in the blood as measured by qPCR as a function of days since infection, mimick-
ing successive cycles of appearance and disappearance (sequestration) of blood parasite gener-
ations. The model parameters capture the following biological processes: the total number of
first generation blood parasites per mL blood (β1); the blood parasite multiplication rate, i.e.
the number of next generation parasites per current generation parasite (β2); the average time
from inoculation to appearance of first generation blood parasites (μ1); the average duration of
the blood parasite stage (μ2); the average time from parasite sequestration (i.e. when a parasite
cannot be detected in the blood) to appearance of next generation parasites (μ3); and the stan-
dard deviation of time of appearance and disappearance of individual blood parasites from a
given generation, which represents the rate at which parasite concentrations change (σ1, lower
values mean higher rate). We assumed that qPCR measurement error follows a lognormal
distribution.
We extended the original model [21] with regard to the following points. We allowed para-
site kinetics to vary between individuals by including random effects for model parameters
β1, β2, and μ1. Given that the nine CHMI experiments (Table 2) were performed at the same
lab, using the same strain, and were performed by the same person (CCH) on the same PCR
machine, we assumed that inter-study variation is negligible relative to inter-individual varia-
tion (i.e. no random intercept for study). Observations below the detection limit of the qPCR
(i.e. censored observations) were explicitly modeled, rather than assuming a value equal to half
the detection limit [21,26] (which would introduce artificial information) or leaving out such
observations altogether [28] (which would ignore information in the data). We further jointly
modeled the probability of detecting parasites through blood microscopy as a function of the
predicted parasite load (i.e. before measurement error or censoring), using a standard hierar-
chical logistic regression model (random intercept for individuals).
Model parameters were jointly estimated in a Bayesian framework, giving several advan-
tages over previously applied classic (frequentist) approaches [21,25,26]. The Bayesian
approach allowed simultaneous estimation of all model parameters and the associated uncer-
tainty (including the model parameters for positive blood microscopy), without the need to
fix a subset of parameters. Furthermore, the Bayesian framework allowed for exact rather
than approximate inferences based on normality assumptions. See S1 Text for a detailed
description of the statistical model and the parameter estimation procedure. Model parameter
estimates are summarized in terms of posterior mean and a 95%-Bayesian credible interval
(95%-BCI), which we defined as the 2.5th and 97.5th percentiles of the posterior samples for
each parameter.
Power analysis
We performed power calculations for erythrocytic and hepatic vaccine trials, using combina-
tions of presumed mean vaccine efficacy (30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% reduc-
tion in number of first-generation parasites or parasite multiplication rate), inter-individual
variation in vaccine effect (beta distribution with standard deviation 0.05 or 0.10), number of
study participants in each group, and the blood sampling frequency: one (8am), two (8am,
4pm), or three (8am, 4pm, 10pm) per day, or once every two days (even days), either in the
morning (8am) or afternoon (4pm). For each combination of assumptions, we simulated ten
thousand repeated vaccine trials, using one posterior draw of model parameters to generate
one set of trial data. We explicitly simulated the probability of blood microscopy turning posi-
tive (and consequent termination of the experiment) as a function of predicted blood parasite
concentrations to arrive at the most realistic individual time series possible. For each repeated
vaccine trial, all individual-level random effects were drawn independently from each other
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(i.e. we did not re-use the random effects estimated from the data). The qPCR detection limit
was set to 20 parasites per mL blood (i.e. the current practice at Radboud University Medical
Center, Nijmegen, The Netherlands).
Because the Bayesian non-linear model used in this study requires a substantial amount of
data (i.e. at least two, preferably three samples per day), each simulated vaccine trial was ana-
lyzed using simple frequentist statistical tests as previously described [23]. First, censored obser-
vations were set to half the value of the detection limit. Next, we categorized data by parasite
cycle (days 6.5–8.5, 8.5–10.5, 10.5–12.5) and calculated the mean log-transformed blood parasite
concentration per parasite cycle and individual. For hepatic vaccine trials, we compared first-
cycle log-blood concentrations between vaccine and control arms with two-sided t-tests (assum-
ing unequal variances due to potential censoring). For asexual erythrocytic vaccine trials, we cal-
culated the differences in average log-blood concentrations between consecutive cycles for each
individual, and then averaged these differences over cycles within individuals. The average dif-
ferences were compared between groups, again with two-sided T-tests (assuming unequal vari-
ances due to potential censoring). The predicted power of a vaccine trial was expressed as the
proportion of repeatedly simulated trials that resulted in a p-value equal to or lower than 0.05.
The validity of using the T-test (i.e. the effective probability of a Type 1 error) was checked in a
similar fashion, but by simulating vaccine trials with zero effect in both treatment arms.
To explore the potential impact of using needle-injected CHMI on vaccine trial power, we
repeated the power calculations assuming that the inter-individual variation in the number of
first-generation parasites is half that of mosquito-based CHMI (i.e. sb1 ;needle ¼ sb1=2, based on
data digitally extracted from Fig 4A in Sheehy et al. 2013 [13]).
We further repeated the power calculation based on an analysis of the data using the sim-
pler log-linear sine model [22], assuming that the parasite generation time is 1.84 days (as esti-
mated by the main model). For the sake of comparison, we improved the log-linear sine model
by adding random effects for starting parasitaemia levels, parasite growth rate, and timing of
the parasite cycle in each individual, and explicitly modeled observations under the qPCR
detection limit (see S1 Text for model details). For the purpose of the power analysis we
assumed that two full parasite cycles would be observed in each individual (the log-linear sine
model does not provide a prediction for termination of an experiment). Other than that, this
power analysis was executed in exactly the same fashion as that based on the main analysis.
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